Hepatitis B
Hepatitis B is an infectious disease caused by the Hepatitis B virus (HBV) that leads to liver inflammation and damage, presenting as either an acute or chronic viral infection. The virus spreads through contact with bodily fluids from an infected person, and symptoms may include abdominal pain, dark yellow urine, fatigue, fever, jaundice, and nausea.
Health Outcomes
- Accelerated Recovery in Immunocompromised Mice
- Aggravated Liver Injury
- Alleviated Liver Injury
- Altered Blood Parameters
- Altered Plasma Metabolite Levels
- Asymptomatic Carrier Status
- Attenuated Hepatic Disorders
- Changed Albumin Level
- Confirmed Safety of Treatment
- Decreased IFN-γ Levels
- Decreased Immune Response to Influenza Vaccination
- Decreased Interferon-Gamma Level
- Efficacy of Postbiotics in Immunocompromised Patients
- Elevated Bile Acid Levels
- Elevated Hepatic Enzyme Levels
- Elevated Serum Alanine Aminotransferase Levels
- Elevated Serum Aspartate Aminotransferase Levels
- Elevated Serum Enzyme Levels
- Elevated Serum Globulin Levels
- Elevated Total IgM Levels
- Enhanced Alkaline Phosphatase Activity
- Enhanced Antibody Secretion
- Enhanced Antioxidant Metabolism
- Enhanced Antipathogenic Activity
- Enhanced Antiviral Response
- Enhanced Cell Viability Under Oxidative Stress
- Enhanced Host Resistance
- Enhanced Immune Evasion
- Enhanced Immune Function
- Enhanced Immune Resistance
- Enhanced Liver Protection
- Enhanced Phenotypic Maturation of Dendritic Cells
- Enhanced Protection Against Infection
- Enhanced T-Cell Response
- Improved Antiviral Effect
- Improved Antiviral Immune Response
- Improved Antiviral Response
- Improved Cell Survival Rates
- Improved Cell-mediated Immunity
- Improved Child-Pugh Score
- Improved Child-Pugh Scores
- Improved Growth in Bile-Containing Medium
- Improved Hepatic Disease
- Improved Hepatic Function
- Improved Hepatopancreas Health
- Improved Histopathological Protection
- Improved Host Health
- Improved IFN-γ Levels
- Improved Immune Cell Counts
- Improved Immune Function
- Improved Immune Response
- Improved Immune Response to Vaccination
- Improved Immune System Modulation
- Improved Immunological Indices
- Improved Immunological Response
- Improved Infection Protection
- Improved Liver Antioxidant Capacity
- Improved Liver Biomarkers
- Improved Liver Disease Biomarkers
- Improved Liver Enzyme Activity
- Improved Liver Enzyme Function
- Improved Liver Function
- Improved Liver Health
- Improved Liver Histology
- Improved Liver Morphology
- Improved Liver Regeneration
- Improved Lower Limit of Detection
- Improved Organ Histology
- Improved Pathogen Clearance
- Improved Pathogen Tolerance
- Improved Phagocytic Activity of Macrophages
- Improved Phagocytic Function
- Improved Protein Synthesis in Liver
- Improved Recovery in Immunocompromised Individuals
- Improved Relative Survival Rate Against Pathogen
- Improved Resistance to Chronic Infections
- Improved Resistance to Pathogenic Infection
- Improved Resistance to Viral Infections
- Improved Seroconversion
- Improved Specific Antibody Response
- Improved Survival Rate Following Infection
- Improved Survival Rate in Digestive Conditions
- Improved Survival Through Digestive Tract
- Improved Vaccine Response in Immunocompromised Hosts
- Improved Vaccine-Specific IgG Levels
- Increased Antibody Response
- Increased Antibody Titer
- Increased Apoptosis
- Increased Aspartate Aminotransferase Concentration
- Increased Aspartate Aminotransferase Level
- Increased Aspartate Transferase Level
- Increased Bile Resistance
- Increased CD3+CD8+ Cell Counts
- Increased CD8+ T Cells
- Increased Cellular Apoptosis
- Increased Conjugated Bile Acid Levels
- Increased Degradation of Non-Assimilated Compounds
- Increased Enzyme Production
- Increased Fecal Excretion of Aflatoxin B1
- Increased Hepatic Antioxidant Enzyme Levels
- Increased Histological Damage
- Increased IgM Concentration
- Increased Immunoglobulin M Levels
- Increased Interferon-Alpha Production
- Increased Liver Enzyme Levels
- Increased NK Cell Count
- Increased Natural Killer Cell Proportion
- Increased Need for Repeated Dosing
- Increased Plasma GLDH
- Increased Plasma Protein Levels
- Increased Protease Activity
- Increased Serum Interferon Gamma Levels
- Increased Serum Peroxidase Activity
- Increased Serum Total Bile Acid Levels
- Increased Specific Antibody Levels
- Increased Survival Against Pathogens
- Increased Survival Rates of Infected Hosts
- Increased Total Bile Acid Levels
- Increased Vaccine-Specific Plasma Immunoglobulin G (IgG)
- Increased Viral Clearance Rate
- Induction of Specific CD8+ T Cells
- Inhibited Hepatitis B Virus Replication
- Liver Histopathological Damage
- Lowered Serum Levels of Liver Injury Markers
- Maintained Albumin Levels
- Maintained Normal ALT Levels
- Maintained Normal Liver Function
- Maintained Safety with Repeated Oral Exposure
- Maintenance of NK Cell Activity
- Modulated Immune Marker IFN-γ
- Neutralized Reactive Oxygen Species
- No Antiviral Effect
- No Change in Fibrosis
- No Cytochrome P450 Induction
- No Measurable IFN-Alpha Induction
- No Significant Change in Aflatoxin Distribution or Metabolism
- Potential Modulation of FGF-19 Levels
- Preserved Liver Function
- Preserved Liver Structure
- Prevented Increase in Total Bilirubin
- Prevented Liver Fibrosis
- Prevented Liver Injury
- Prevented Liver Pathway Dysregulation
- Protection Against Pathogen Dissemination
- Reduced AFB1-Induced Liver Damage
- Reduced ALT Levels
- Reduced AST Levels
- Reduced Abnormal Increase in Bilirubin
- Reduced Acute Liver Injury
- Reduced Alanine Transaminase Levels
- Reduced Ammonia Levels
- Reduced Apoptosis Induced by Pathogens
- Reduced Aspartate Aminotransferase Levels
- Reduced Aspartate Transaminase Activity
- Reduced Bilirubin Levels
- Reduced Butyrylcholinesterase Activity
- Reduced Cancer Incidence
- Reduced Cancer Mortality
- Reduced Cell Viability
- Reduced Clonorchiasis Severity
- Reduced Cumulative Mortality from Vibrio vulnificus
- Reduced Cytotoxicity
- Reduced Disease Incidence
- Reduced Elevated Liver Enzymes
- Reduced Elevated Serum Alanine Aminotransferase (ALT)
- Reduced Extracellular HBsAg Levels
- Reduced Fibrosis Marker Levels
- Reduced GPT Level
- Reduced Glutamyl Pyruvic Transaminase Levels
- Reduced Harmful Enzyme Activity
- Reduced Hepatic Apoptosis
- Reduced Hepatic Damage Indices
- Reduced Hepatic Glycogen Levels
- Reduced Hepatic Histological Injury
- Reduced Hepatic Inflammation
- Reduced Hepatic Inflammation Markers
- Reduced Hepatic Inflammation and Oxidative Stress
- Reduced Hepatic Inflammatory Cytokines
- Reduced Hepatic Nitric Oxide Production
- Reduced Hepatocellular Carcinoma Progression
- Reduced Hepatocellular Carcinoma Recurrence
- Reduced Hepatocellular Damage
- Reduced Hepatocyte Necrosis
- Reduced Hepatotoxicity
- Reduced Hepatotoxicity from Iron Oxide Nanoparticles
- Reduced Histological Damage
- Reduced Histological Liver Injury
- Reduced Histological Scores
- Reduced IFN-γ Levels
- Reduced Incidence of Abnormal Increase in Alkaline Phosphatase
- Reduced Incidence of Hyperbilirubinemia
- Reduced Incidence of Liver Cancer
- Reduced Infection Rate
- Reduced Interferon-Gamma Levels
- Reduced Liver Biochemical Markers
- Reduced Liver Damage
- Reduced Liver Damage Indicators
- Reduced Liver Damage Markers Levels
- Reduced Liver Disease Progression
- Reduced Liver Disease Symptoms
- Reduced Liver Enzyme Activity
- Reduced Liver Fibrosis
- Reduced Liver Function
- Reduced Liver Function Indicators
- Reduced Liver Inflammation
- Reduced Liver Inflammation Fibrosis Score
- Reduced Liver Injury
- Reduced Liver Injury Indicators
- Reduced Liver Injury Marker
- Reduced Liver Lesion Severity
- Reduced Liver Oxidative Damage
- Reduced Liver Oxidative Stress Injury
- Reduced Liver Stiffness
- Reduced Liver Toxicity
- Reduced Lobular Inflammation
- Reduced M1 Macrophage Population
- Reduced Microbial Translocation to the Liver
- Reduced Mortality Rate During Pathogen Challenge
- Reduced Organ Injury
- Reduced Pathogen Counts in Organs
- Reduced Pathogen Infection
- Reduced Pathogen Load in Visceral Organs
- Reduced Pathogen Viability
- Reduced Pathological Changes of Liver
- Reduced Risk of Infection
- Reduced Risk of Pathogen Dissemination
- Reduced Serum Alanine Aminotransferase Activity
- Reduced Serum Alanine Aminotransferase Levels
- Reduced Serum Gamma Glutamine Transaminase Levels
- Reduced Serum Haptoglobin Concentration
- Reduced Serum Transaminase Levels
- Reduced Susceptibility to Infection
- Reduced Total Infections
- Reduced Toxin-induced Cytotoxicity
- Reduced Viral Activity
- Reduced Viral Binding
- Reduced Viral Clearance Time
- Reduced Viral Entry
- Reduced Viral Infection
- Reduced Viral Infection Incidence
- Reduced Viral Load
- Reduced Virulence Factors
- Reduced Virulence of Pathogens
- Reduced Virus Titer
- Regenerated Hepatic Tissue
- Restored T-Cell Population
- Significant Histopathological Changes in Liver
- Stabilized Total Bilirubin Levels
- Stable Alanine Aminotransferase Levels
- Stable Aspartate Aminotransferase Levels
- Sustained Immune Activity
- White Blood Cell Count